FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4225101038> ?p ?o ?g. }

• W4225101038 abstract "Age-related macular degeneration (AMD) is a common and chronic eye condition characterized by the presence of progressive degenerative abnormalities in the central retina (macula). Notably, neovascular, or wet, AMD (nAMD) occurs when new, abnormal blood vessels grow under the macula causing scarring of the macula itself and resulting in a loss of central vision, visual distortion, and an impaired capacity of perceiving colour contrast and intensity. Brolucizumab, a new generation anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, was approved by the European Medicines Agency for the treatment of nAMD. The aim of this analysis is to evaluate the cost-effectiveness profile of brolucizumab, compared to the main therapeutic alternative available (aflibercept), for the treatment of nAMD.The simulation of costs and outcomes was carried out using a Markov model over a time horizon of 15 years. In base-case, treatment effectiveness inputs for brolucizumab and aflibercept were extracted from the HAWK and HARRIER studies and from a network meta-analysis. The Italian National Healthcare Service (NHS) perspective was considered, therefore only healthcare direct costs (treatment acquisition, administration, adverse events, disease monitoring) were analysed. In the alternative scenarios, the societal perspective and a prolonged time horizon were considered. Model robustness was tested through sensitivity analyses.In the base-case analysis, brolucizumab was dominant over aflibercept (+ 0.11 years QALY gained and -€15,679 costs). Both one-way deterministic and probabilistic sensitivity analyses confirmed the robustness and reliability of base-case results. The results of the probabilistic sensitivity analysis showed that when the willingness to pay is equal to €50,000 per QALY gained, brolucizumab would be dominant in 84% of simulations and in the remaining simulations brolucizumab would be cost-effective compared to aflibercept. Results of the alternative scenarios and sensitivity analyses confirmed the results of base-case.The cost-utility analysis shows that brolucizumab is dominant over aflibercept. Treatment with brolucizumab reduces the economic impact of nAMD and determined a slight increase of quality-adjusted survival. This analysis gives a high level of confidence that the treatment with brolucizumab would reduce the burden of intravitreal injections, compared to aflibercept, a relevant therapeutic alternative in Italy." @default.
• W4225101038 created "2022-04-30" @default.
• W4225101038 creator A5002285550 @default.
• W4225101038 creator A5005740308 @default.
• W4225101038 creator A5053733069 @default.
• W4225101038 creator A5071389579 @default.
• W4225101038 date "2022-04-29" @default.
• W4225101038 modified "2023-10-14" @default.
• W4225101038 title "Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy" @default.
• W4225101038 cites W169143942 @default.
• W4225101038 cites W1696340081 @default.
• W4225101038 cites W2006652444 @default.
• W4225101038 cites W2070716505 @default.
• W4225101038 cites W2072439859 @default.
• W4225101038 cites W2079794035 @default.
• W4225101038 cites W2101421486 @default.
• W4225101038 cites W2162119052 @default.
• W4225101038 cites W2616502721 @default.
• W4225101038 cites W2734721636 @default.
• W4225101038 cites W2738996050 @default.
• W4225101038 cites W2763342840 @default.
• W4225101038 cites W2936430874 @default.
• W4225101038 cites W4247214019 @default.
• W4225101038 doi "https://doi.org/10.1186/s12913-022-07972-w" @default.
• W4225101038 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35484540" @default.
• W4225101038 hasPublicationYear "2022" @default.
• W4225101038 type Work @default.
• W4225101038 citedByCount "4" @default.
• W4225101038 countsByYear W42251010382022 @default.
• W4225101038 countsByYear W42251010382023 @default.
• W4225101038 crossrefType "journal-article" @default.
• W4225101038 hasAuthorship W4225101038A5002285550 @default.
• W4225101038 hasAuthorship W4225101038A5005740308 @default.
• W4225101038 hasAuthorship W4225101038A5053733069 @default.
• W4225101038 hasAuthorship W4225101038A5071389579 @default.
• W4225101038 hasBestOaLocation W42251010381 @default.
• W4225101038 hasConcept C118487528 @default.
• W4225101038 hasConcept C119767625 @default.
• W4225101038 hasConcept C141071460 @default.
• W4225101038 hasConcept C2776403814 @default.
• W4225101038 hasConcept C2776694085 @default.
• W4225101038 hasConcept C2777802072 @default.
• W4225101038 hasConcept C2778749236 @default.
• W4225101038 hasConcept C2781100027 @default.
• W4225101038 hasConcept C2781359195 @default.
• W4225101038 hasConcept C71924100 @default.
• W4225101038 hasConceptScore W4225101038C118487528 @default.
• W4225101038 hasConceptScore W4225101038C119767625 @default.
• W4225101038 hasConceptScore W4225101038C141071460 @default.
• W4225101038 hasConceptScore W4225101038C2776403814 @default.
• W4225101038 hasConceptScore W4225101038C2776694085 @default.
• W4225101038 hasConceptScore W4225101038C2777802072 @default.
• W4225101038 hasConceptScore W4225101038C2778749236 @default.
• W4225101038 hasConceptScore W4225101038C2781100027 @default.
• W4225101038 hasConceptScore W4225101038C2781359195 @default.
• W4225101038 hasConceptScore W4225101038C71924100 @default.
• W4225101038 hasIssue "1" @default.
• W4225101038 hasLocation W42251010381 @default.
• W4225101038 hasLocation W42251010382 @default.
• W4225101038 hasLocation W42251010383 @default.
• W4225101038 hasOpenAccess W4225101038 @default.
• W4225101038 hasPrimaryLocation W42251010381 @default.
• W4225101038 hasRelatedWork W1428301736 @default.
• W4225101038 hasRelatedWork W2049577742 @default.
• W4225101038 hasRelatedWork W2319930158 @default.
• W4225101038 hasRelatedWork W2412677897 @default.
• W4225101038 hasRelatedWork W2577193304 @default.
• W4225101038 hasRelatedWork W2766371567 @default.
• W4225101038 hasRelatedWork W2769959318 @default.
• W4225101038 hasRelatedWork W3124250718 @default.
• W4225101038 hasRelatedWork W833702363 @default.
• W4225101038 hasRelatedWork W3122143690 @default.
• W4225101038 hasVolume "22" @default.
• W4225101038 isParatext "false" @default.
• W4225101038 isRetracted "false" @default.
• W4225101038 workType "article" @default.